肥胖对血管质量倡议中静脉腔内消融结局的影响
基于Vascular Quality Initiative Varicose Vein Registry数据,分析10,494例(12,955条肢体)接受主干静脉腔内消融±同时行静脉切除术的患者,发现较高BMI者术前疾病更重,但rVCSS和症状总分改善概率仍>92%,BMI不增加并发症风险,仅在单纯消融者中与再通风险增加相关(aOR 1.26/5点BMI)。
要点
- 较高BMI者术前rVCSS和症状评分更差,但消融±静脉切除术后的改善概率仍>92%。
- BMI不增加手术相关或长期随访并发症风险。
- 单纯消融者中较高BMI与再通风险增加相关,加做静脉切除术可能改善结局。
核心结论
- 较高BMI患者术前疾病更重,但各BMI范围均维持很高的改善率。
- 较高BMI不增加并发症率。
- 较高BMI者加做静脉切除术可能改善结局并降低再通可能性。
- 考虑到减重困难,延迟静脉手术直至减重可能使患者无法接受有指征且有效的治疗。
研究设计与样本
- 回顾性队列研究,使用Vascular Quality Initiative Varicose Vein Registry数据。
- 纳入2015年1月至2025年10月接受主干静脉腔内消融(激光或射频)伴或不伴静脉切除术的成人患者。
- 共10,494例患者(12,955条肢体),女性68.6%,平均BMI 29.9 kg/m2,51.2%同时行静脉切除术。
- 中位随访60天(四分位距16-133天)。
- 以BMI为主要解释变量,采用双变量统计和多变量logistic回归模型评估混杂。
主要发现
- 较高BMI者术前rVCSS和症状总分更高。
- 消融加静脉切除术者rVCSS和症状总分改善的预测概率>92%。
临床怎么用
- 不应仅因较高BMI而延迟有指征的静脉腔内消融,因各BMI范围改善率均很高且并发症未增加。
- 对较高BMI患者,可考虑加做静脉切除术以改善结局并降低再通可能性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity is a known risk factor for chronic venous insufficiency in both incidence and disease severity. Limited previous work suggests that obesity is associated with worse outcomes after endovenous ablation. We analyzed patients who received truncal endovenous ablation with or without concomitant phlebectomy to better understand the relationship between obesity and postoperative outcomes. METHODS: We evaluated short- and long-term clinical and patient-reported outcomes among patients who underwent truncal endovenous ablation with and without phlebectomy in the Vascular Quality Initiative Varicose Vein Registry with body mass index (BMI) as the primary explanatory variable. Our primary outcome measures were improvement in revised Venous Clinical Severity Score (rVCSS) and total symptom score. Secondary outcomes included complications and recanalization of target vein. Pre- and postprocedural comparisons were performed using bivariate statistics, and multivariable logistic regression models were used to assess for confounding. RESULTS: From January 2015 to October 2025, we identified 10,494 adult patients (12,955 limbs) who underwent truncal endovenous ablation with either laser or radiofrequency ablation. Patients were 68.6% female, with a mean BMI of 29.9 kg/m2. A total of 51.2% of patients underwent concomitant phlebectomy. Median follow-up was 60 days (interquartile range, 16-133). Patients with higher BMI had higher preoperative rVCSS and total symptoms scores. The predicted probability of improvement in rVCSS and total symptom score was >92% for patients undergoing endovenous ablation with phlebectomy. BMI was not associated with increased rates of procedure-related complications or long-term follow-up complications [adjusted odds ratio (aOR), 1.12; 95% confidence interval (CI), 0.89-1.41; P = .34; aOR, 1.00; 95% CI, 0.92-1.08; P = .98, respectively for five-point change in BMI]. In patients receiving ablation alone, BMI was associated with increased risk of recanalization (aOR for five-point change in BMI, 1.26; 95% CI, 1.06-1.5; P = .009) CONCLUSIONS: Despite patients with higher BMI having worse preoperative disease, patients sustain very high rates of improvement across the BMI spectrum. Further, higher BMI was not associated with increased rates of complications. The addition of phlebectomy in patients with higher BMI may improve outcomes and reduce likelihood of recanalization. Given the difficulty of achieving meaningful weight loss, delaying venous procedures until weight loss is achieved may prevent patients from receiving indicated and effective treatment.
引用
- Levy S, Johnson PL, Fleischer CM, et al. Effect of obesity on endovenous ablation outcomes in the Vascular Quality Initiative. J Vasc Surg Venous Lymphat Disord. 2026. PMID: 42462908. doi:10.1016/j.jvsv.2026.102578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。